美托洛尔用于老年COPD合并冠心病史治疗的临床疗效观察

目的:探讨美托洛尔(β1受体阻滞剂)用于老年COPD合并冠心病史治疗的临床疗效。方法:选取2018年6月—2019年6月在我院接受治疗的60岁以上(包括60岁)COPD合并冠心病史老年患者,分为对照组与观察组。对照组给予接受布地奈德福莫特罗粉吸入剂治疗,观察组在使用布地奈德福莫特罗粉吸入剂治疗的基础上口服琥珀酸美托洛尔缓释片治疗,观察对比两组治疗效果。结果:观察组临床治疗效果优于对照组,观察组住院时长以及并发症的发生率低于对照组(P<0.05),差异具有统计学意义。结论:老年COPD合并冠心病史接受美托洛尔治疗,可有效缩短住院时长、用药效果明显、有效提升用药安全性,值得临床推广。

Clinical observation of metoprolol in the treatment of elderly patients with COPD and coronary heart disease history

Objective:To investigate the clinical efficacy of metoprolol(beta 1 receptor blocker)in the treatment of elderly patients with COPD and coronary heart disease history.Methods:All patients were over 60 years old(including 60 years old)who were treated in our hospital during the same period from June 2018 to June 2019.The elderly patients with COPD and coronary heart disease history were divided into control group and observation group.The patients in control group were treated with budesonide formoterol powder inhalation.The patients in observation group were treated with metoprolol succinate sustained-release tablets on the basis of budesonide formoterol powder inhalation.Therapeutic effect.Results:The clinical effect of the observation group was better than that of the control group.The length of hospitalization and the incidence of complications in the observation group were lower than those in the control group(P<0.05).There were significant differences in the data.Conclusion:Metoprolol treatment for COPD patients with history of coronary heart disease can effectively shorten the length of hospitalization,improve drug safety,and is worthy of clinical application.